SCHEMBL17898211

SCHEMBL17898211

Cc1nccc(C2CCCN(C(=O)OC(C)(C)C)C2)n1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TRPV3 Q8NET8 2/20 0.51
PRMT5 O14744 1/20 0.49
HPGDS O60760 2/20 0.48
JAK2 O60674 1/20 0.47
JAK1 P23458 1/20 0.47
MAP4K4 O95819 1/20 0.44
ALOX5AP P20292 1/20 0.43
FEN1 P39748 1/20 0.43
GPR119 Q8TDV5 4/20 0.43
MAP3K12 Q12852 3/20 0.43
PROKR1 Q8TCW9 2/20 0.43
ALDH1A1 P00352 2/20 0.42
KDM4E B2RXH2 1/20 0.42
GLA P06280 1/20 0.42
HPGD P15428 1/20 0.42
RECQL P46063 1/20 0.42
HSD17B10 Q99714 1/20 0.42
MEN1 O00255 1/20 0.42
MAPT P10636 1/20 0.42
KMT2A Q03164 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17898219 0.87 TRPV3 (0.50) TRPV3PRMT5HPGDSJAK2JAK1
SCHEMBL21604683 0.82 ALDH1A1 (0.47) TRPV3PRMT5HPGDSJAK2JAK1
SCHEMBL17672428 0.81 TRPV3 (0.49) TRPV3HPGDSGPR119HPGDHSD17B10
SCHEMBL30919809 0.81 GPR119 (0.55) TRPV3PRMT5HPGDSJAK2JAK1
SCHEMBL4003240 0.81 GPR119 (0.55) TRPV3PRMT5HPGDSJAK2JAK1
SCHEMBL16210779 0.81 TRPV3 (0.46) TRPV3PRMT5HPGDSJAK2JAK1
SCHEMBL20281685 0.79 PROKR1 (0.56) PRMT5HPGDSJAK2JAK1PROKR1
SCHEMBL31383657 0.79 TRPV3 (0.53) TRPV3PRMT5HPGDSJAK2JAK1
SCHEMBL9962296 0.79 TRPV3 (0.53) TRPV3PRMT5HPGDSJAK2JAK1
SCHEMBL17682532 0.79 TRPV3 (0.47) TRPV3PRMT5HPGDSGPR119KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20160194303-A1 HETEROCYCLES CAPABLE OF MODULATING T-CELL RESPONSES, AND METHODS OF USING SAME NOGRA PHARMA LIMITED (IE) 2016-07-07 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160194303-A1 HETEROCYCLES CAPABLE OF MODULATING T-CELL RESPONSES, AND METHODS OF USING SAME ICOS, NFATC1, CD74 TRPV3 1521/4885PRMT5 2271/4885HPGDS 13/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.